Study of IBI3020 for Late-Stage Solid Tumors
This study is testing a new targeted therapy called IBI3020 for people with late-stage solid tumors. IBI3020 is a recombinant anti-CEACAM5 monoclonal antibody - dual-payload conjugate for injection. The main goal is to understand how safe IBI3020 is and to find the best dose to use. Researchers will be looking for any side effects and changes in physical exams or heart tests over a period of up to three years. You may be able to join if you are between 18 and 75 years old and have a solid tumor. This study is currently recruiting participants.
- Study design
- This is an interventional study planning to enroll 285 participants. It is designed to evaluate the safety and tolerability of IBI3020.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 3 years to monitor for adverse events and changes in physical examination and electrocardiogram results.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
At a glance
Conditions
NCT06963281
Where you'd take part
This study runs at 9 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Mayo Clinic - Arizona
Pheonix, Arizonastudy coordinator listed
Recruiting
Mayo Clinic - Florida
Jacksonville, Floridastudy coordinator listed
Recruiting
Mayo Clinic - Rochester
Rochester, Minnesotastudy coordinator listed
Recruiting
Montefiore Cancer Center
New York, New Yorkstudy coordinator listed
Recruiting
NEXT Dallas
Irving, Texasstudy coordinator listed
Recruiting
NEXT Houston
Houston, Texasstudy coordinator listed
Recruiting
Shandong Cancer Hospital
Jinan, Shandong, Chinastudy coordinator listed
Recruiting
Shanxi Cancer Hospital
Taiyuan, Shanxi, Chinastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Numbers of subjects with adverse eventsUp to 3 years
defined as any untoward medical occurrence, whether or not there is a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed
- Number of subjects with clinically significant changes in physical examination resultsUp to 3 years
Clinically significant abnormal physical examination findings reported by the investigator.
- Number of subjects with clinically significant changes in electrocardiogramUp to 3 years
Clinically significant abnormal electrocardiogram findings reported by the investigator.
- Number of subjects with clinically significant changes in vital signsUp to 3 years
Vital signs including body temperature, pulse, respiratory rate, oxygen saturation by pulse oximetry at rest and blood pressure
- Dose limiting toxicities (DLTs)Up to 21 days
Dose limiting toxicities (DLTs) to establish MTD and/or RP2D.
- objective response rate (ORR)Up to 3 years
objective response rate (ORR) as evaluated per the RECIST v1.1 criteria.
- Number of subjects with clinically significant changes in laboratory parametersUp to 3 years
Clinically significant abnormal laboratory parameters findings reported by the investigator.